DISON I - Directly Integrated Suction and Optics System for the Treatment of Nephrolithiasis (DISON I)
DISON I - Directly Integrated Suction and Optics System for the Treatment of Nephrolithiasis- A Multicenter Prospective Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Matt Sprinkel
- Phone Number: +1 650 465 6200
- Email: matt@ventarissurgical.com
Study Locations
-
-
-
Buenos Aires, Argentina
- Hospital Aleman
-
Contact:
- Head of Clinical Investigations
- Phone Number: 2286/ 7039 (011) 4827 7000
- Email: pperez@hospitalaleman.com
-
-
-
-
-
Montreal, Canada
- Centre hospitalier de l'Université de Montréal (CHUM)
-
Contact:
- Research Coordinator
- Phone Number: 22931 514-890-8000
- Email: abbas.guennoun.chum@ssss.gouv.qc.ca
-
-
-
-
-
Hong Kong, Hong Kong
- The Chinese University of Hong Kong
-
Contact:
- Research Coordinator
- Phone Number: 3505 2211
- Email: francolai@surgery.cuhk.edu.hk
-
-
-
-
-
Nadiād, India
- Muljibhai Patel Urological Hospital
-
Contact:
- Research Coordinator
- Phone Number: 912682520328
- Email: monil.parmar@mpuh.in
-
-
-
-
-
Tauranga, New Zealand
- Tauranga Urology Research Limited
-
Contact:
- Research Coordinator
- Phone Number: (07) 579 0466
- Email: marg@urobop.co.nz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of calyceal and/or renal pelvis calculi
- Age from 18 through 85 years
- Maximum stone diameter between 0.5cm - 2.0cm as assessed by Non-Contrast CT scan (≤ 2 mm slice thickness) within 90 days prior to treatment
- Willing and able to comply with all study requirements
- Signs study-specific informed consent form
Exclusion Criteria:
- Diagnosis of calculus of the ureter
- BMI ≥ 42
- Significant renal impairment: stage 3a CKD or higher (eGFR <59mL/min)
- Active infection, including urinary tract infection
- Urological anatomic/congenital abnormalities
- Previous history of struvite stone in the same renal unit
- Taking anticoagulants that cannot be stopped before and after procedure or known coagulopathy or platelet disorder (except aspirin below 100mg/d)
- History of gross hematuria
- Solitary functioning kidney
- Known allergy to device materials
- Any severe illness that would prevent complete study participation or confound study results
- Serious concurrent medical conditions such as heart disease (e.g., myocardial infarction within 30 days, congestive heart failure - NYHA Class IV), pulmonary disease or uncontrolled diabetes.
- History of open-heart surgery, or cardiac arrest < 180 days prior to the date of informed consent
- ASA III or higher
- Taking systemic immune suppressants
- Dementia or psychiatric condition that prevents the participant from completing required follow up
- Contraindication to both general and spinal anesthesia
- Participating in another investigational study that could affect responses to the study device
- Unwilling to accept a transfusion should one be required
- Pregnant or considering getting pregnant within the next 3 months
- Undergoing bilateral ureteroscopy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Investigational endourological device used during retrograde intrarenal surgery.
|
Investigational endourological device used during retrograde intrarenal surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Procedure success
Time Frame: Intraoperative
|
Successful completion of the planned procedure without device-related technical complications.
|
Intraoperative
|
|
Stone-Free Status
Time Frame: 30 days post-procedure
|
Absence of residual stone fragments on CT imaging
|
30 days post-procedure
|
|
Serious Adverse Device Effects (SADEs)
Time Frame: 30 days post-procedure
|
Serious adverse device effects related to the investigational device.
|
30 days post-procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stone-Free Categories
Time Frame: 30 days post-procedure
|
Stone-free status according to predefined categories.
|
30 days post-procedure
|
|
Intrarenal pressure assessment
Time Frame: Intraoperative
|
Intrarenal pressure measured during the procedure.
|
Intraoperative
|
|
Procedure duration
Time Frame: Intraoperative
|
Duration of the surgical procedure.
|
Intraoperative
|
|
Stone clearance
Time Frame: Intraoperative
|
Amount of stone material removed during the procedure.
|
Intraoperative
|
|
Residual stone burden
Time Frame: 30 days post-procedure
|
Residual stone burden assessed by imaging.
|
30 days post-procedure
|
|
Device- or procedure-related adverse event
Time Frame: From procedure to 12 months post-procedure
|
Device- or procedure-related adverse event.
|
From procedure to 12 months post-procedure
|
|
Stone-related healthcare utilization
Time Frame: From procedure to 12 months post-procedure
|
Healthcare utilization related to recurrent stone symptoms in the treated kidney.
|
From procedure to 12 months post-procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Calculi
- Pathological Conditions, Anatomical
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urinary Calculi
- Pathological Conditions, Signs and Symptoms
- Kidney Calculi
- Nephrolithiasis
- Urolithiasis
Other Study ID Numbers
Other Study ID Numbers
- VS-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.